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Oxidative stress and nitric oxide synthase in rat diabetic ne- An increased production of reactive oxygen species
phropathy: Effects of ACEI and ARB. (ROS), including superoxide anion (O2 ) may contribute
Background. Angiotensin II (Ang II) can up-regulate nico- to diabetic complications [1–9] although the source oftinamide adenine dinucleotide phosphate [NAD(P)H] oxidase,
O2 remains unclear. The phagocyte contains a potentwhose product superoxide anion (O2 ) can interact with nitric
ROS-generating nicotinamide adenine dinucleotide phos-oxide (NO) to form peroxynitrite (ONOO). We tested the hy-
pothesis that Ang II subtype 1 (AT1) receptor activation en- phate [NAD(P)H] oxidase that is composed of five major
hances oxidative stress and nitrotyrosine deposition in the kid- subunits. There are two membrane-associated proteins,
neys of rats with diabetes mellitus (DM). p22phox and gp91phox, and three major cytosolic com-Methods. After two weeks of streptozotocin-induced DM,
ponents, p47phox, p40phox, and p67phox [10]. While en-rats received either no treatment, an angiotensin-converting
dothelial cells express gp91phox, rodent vascular smoothenzyme inhibitor (ACEI) or an angiotensin receptor blocker
(ARB) for two weeks. At four weeks, renal expression of the muscle cells express a different isoform termed MOX-1
p47phox component of NAD(P)H oxidase, endothelial nitric [11] and, in the kidney, the gp91phox is replaced in cer-
oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS),
tain tubule cells with another isoform termed Renox [12].and nitrotyrosine were evaluated by Western blot and immuno-
O2 reacts with NO with great affinity to produce peroxy-histochemistry and related to plasma lipid peroxidation prod-
ucts (LPO), hydrogen peroxide production in the kidney and nitrite (ONOO) [13], which is a weak agonist for activa-
24-hour protein excretion. tion of cGMP [14]. Therefore, O2 effectively inactivates
Results. Immunoreactive expression of p47phox and eNOS nitric oxide (NO). However, ONOO is a potent oxidant
were increased in DM with an increase in plasma LPO, renal
that can modify proteins. Nitrated tyrosine epitopes pro-hydrogen peroxide production and nitrotyrosine deposition. Ex-
vide a marker for oxidative/nitrosative stress induced bypression of nNOS was unaltered. Treatment with either ACEI
or ARB prevented all these findings and also prevented signifi- the interaction of O2 and NO, and may be pathogenic
cant microalbuminuria. The treatments did not affect the ele- by changing protein structure and function [15, 16].
vated blood sugar, nor did DM or its treatment affect the blood An analogous NAD(P)H oxidase system has been re-pressure or the creatinine clearance.
ported in kidney [12, 17–21]. The p47phox is extensivelyConclusion. Early proteinuric diabetic nephropathy increases
regulated. During acute activation, the enzyme is phos-renal expression of the p47phox component of NAD(P)H oxi-
dase and eNOS with increased indices of systemic and renal phorylated and dephosphorylated in parallel with activa-
oxidative/nitrosative stress. An ACEI or an ARB prevents these tion and inactivation of oxidase activity [22]. Up-regula-
changes and prevents the development of proteinuria, indepen- tion of p47phox is seen in the kidneys of spontaneouslydent of blood pressure or blood sugar. This finding indicates
hypertensive rat (SHR), which is a model of angioten-a pathogenic role for AT1 receptors in the development of oxi-
dative damage in the kidneys during early DM. sin II subtype 1 (AT1) receptor-dependent oxidative stress
(abstract; Chabrashvili et al, J Am Soc Nephrol 10:343A,
1999) [23]. In vascular smooth muscle cells p47phox is
linked to Ang II-dependent JAK/STAT signaling events
that underlie proliferation [24]. Therefore, our initial stud-
ies have focused on the p47phox component, althoughKey words: nitric oxide, reactive oxygen species, superoxide anion,
nitrotyrosine, proteinuria, AT1 receptor. in vasculature angiotensin II (Ang II) also up-regulates
p22phox [25] and p67phox [26]. The activation of NADReceived for publication April 25, 2001
(P)H oxidase in diabetes mellitus (DM) is postulated toand in revised form August 2, 2001
Accepted for publication August 31, 2001 suppress the action of NO [3, 7, 8], to increase the expres-
sion of the mRNA for transforming growth factor-1 2002 by the International Society of Nephrology
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(TGF-1) and fibronectin in the glomerulus [4, 5], to de- (DM  QUI; N  7), composed of animals treated with
the ACEI quinapril (Yoshitomi Pharmaceutical Indus-crease the expression of matrix metalloproteinases, and
to increase the expression of the tissue inhibitor of me- tries, Fukuoka, Japan; 3 mg · kg1 · day1 in drinking
water changed daily to quantify the volume intake) andtalloproteinases in the kidney [2, 6]. These diverse ef-
fects could contribute to the pathophysiology of diabetic candesartan-treated group (DM  CAN; N  8), com-
posed of rats treated with a continuous subcutaneousnephropathy (DN) [7, 8]. We recently have shown that
acetylcholine-induced endothelium-dependent relaxation infusion of candesartan (Takeda Chemical Industries,
Tokyo, Japan; 0.05 mg · kg1 · day1 from an osmoticfactor (EDRF) in the rabbit isolated perfused afferent
arteriole can be ascribed to NO [9]. This EDRF response minipump, Alzet Pharmaceuticals, Palo Alto, CA, USA).
Twenty-four-hour urine was collected using metabolicis absent in arterioles microdissected from kidneys of
rabbits with early streptozotocin-induced DM, but a par- cages at 0, 2 and 4 weeks after STZ injection.
Four weeks after induction of diabetes mellitus, ani-tial response can be restored by a membrane-permeable
nitroxide, tempol, that acts as a superoxide dismutase mals were anesthetized with pentobarbital (50 mg/kg
body weight). The abdominal aorta was cannulated and(SOD) mimetic [9]. While these data implicate the poten-
tial importance of oxidative stress in functional NO defi- blood pressure was measured by a pressure transducer
(Nihon Kohden, Tokyo, Japan), blood was collected andciency in diabetic nephropathy, the sources of O2 remain
unclear since other oxidases, including constitutive nitric the kidneys were perfused retrogradely with ice-cold
phosphate-buffered saline (PBS) followed by perfusionoxide synthase (NOS), lipooxygenase, and xanthine oxi-
dase all can contribute to oxidative stress in other models with periodate-lysine-paraformaldehyde (PLP) solution.
Kidney slices for immunohistochemical study were im-of hypertension or renal pathology [27–29].
Angiotensin-converting enzyme inhibitors (ACEIs) mersed in PLP solution overnight at 4C and embedded
in wax (polyethylene glycol 400 distearate; Polysciences[30–32] and angiotensin receptor blockers (ARBs) [33, 34]
have beneficial effects on proteinuria in human diabetic Inc., Warrington, PA, USA). These methods have been
described in detail previously [35, 36].nephropathy. However, it is not clear whether these drugs
can alter oxidative stress in diabetic kidneys.
Measurement of lipid peroxidation, hydrogenThe first aim of this study was to evaluate the expres-
peroxide, creatinine, albumin and glucosesion of the p47phox component of NAD(P)H oxidase
and constitutive NOS in the kidneys of rats during early The lipid peroxidation products in plasma were mea-
sured by thiobarbituric acid method [37]. After precipi-streptozotocin-induced experimental diabetes mellitus,
and to relate these changes in indices of oxidative and tation of proteins with 10% trichloroacetic acid, each
100 L of sample was mixed with 100 L of 4% sodiumnitrosative stress and glomerular damage. The second aim
was to contrast the effects of an ACEI (quinapril; QUI) dodecyl sulfate (SDS), 400 L of 20% acetic acid at pH
3.5 and 400 L of 0.8% 4,6-dihydroxy-2-mercaptopyri-and an ARB (candesartan; CAN) on these parameters.
midine (2-thiobarbituric acid, TBA; Wako Pure Chemi-
cal Industries LTD., Osaka, Japan). After a 60-minute in-
METHODS
cubation at 95C, the malondialdehyde (MDA) formed
Animal preparation was measured by fluorophotometry (Hitachi H-2000,
Tokyo, Japan) with an excitation/emission wavelengthFemale Sprague-Dawley rats weighing 180 to 240 g
were purchased from Charles River Laboratories (Shizu- at 515/553 nm.
Hydrogen peroxide (H2O2) production in kidney ho-oka, Japan). The animals were housed in a temperature-
and humidity-controlled room with 12-hour light/dark mogenates was measured using the 2,7-dichlorodi-
hydrofluorescein-diacetate (DCFH-DA) method as de-cycles, and they were fed standard laboratory animal
chow. Except for the quinapril-treated group, rats had scribed previously [38]. Briefly, 100 g of protein of kid-
ney homogenate was incubated with 16 g  mL1 finalfree access to tap water. Diabetes was induced by a
single tail vein injection of streptozotocin (60 mg/ kg concentration of DCFH-DA (Molecular Probes, Eu-
gene, OR, USA) for 20 minutes at 37C. DCFH-DAbody weight; Sigma Chemical Co., St. Louis, MO, USA)
diluted in citrate buffer, pH 4.5. Nondiabetic control rats is oxidized to the highly fluorescent compound, 2,7-
dichlorofluorescein (DCF) in the presence of H2O2. After(N  11) were injected with an equal volume of citrate
buffer. After three days, the induction of diabetes was centrifugation, the fluorescence of the supernatant was
measured in a spectrofluorometer with excitation/emis-confirmed by measurement of blood glucose concen-
tration. sion wavelength at 485/535 nm.
Creatinine in urine and blood was measured by theTwo weeks after streptozotocin injection, the diabetic
rats were randomly divided into three groups matched Jaffe method using spectrophotometer. The albumin in
urine was quantified by enzyme-linked immunosorbentfor body weight and blood glucose: diabetes mellitus
alone group (DM, N  11); quinapril-treated group assay (ELISA) kit (Panaform Lab., Kumamoto, Japan).
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Table 1. Effect of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) treatment on physiological
and biochemical parameters in diabetes mellitus
Control DM DMQUI DMCAN
(N11) (N11) (N7) (N8)
Body weight g 288.5	7.4 237.0	6.4b 186.4	10.8cd 228.1	12.1ce
Blood glucose mg/dL 132.2	8.5 389.1	26.7c 415.3	64.9c 447.0	40.2c
Mean blood pressure mm Hg 79.7	4.7 85.6	6.0 85.2	2.9 81.0	5.1
Creatinine clearance mL/min/100 g body weight 0.53	0.05 0.59	0.06 0.53	0.11 0.63	0.08
Urinary albumin mg/day 0.12	0.02 1.23	0.39b 0.29	0.09d 0.51	0.16d
Blood LPO nmol/L/mL 0.35	0.11 0.69	0.10a 0.33	0.08d 0.34	0.07d
DCF generation from DCFH-DA
fluorescence unit/lg protein 3.78	0.13 4.62	0.20a 3.85	0.22d 3.72	0.33d
Abbreviations are: DM, diabetes mellitus; QUI, quinapril; CAN, candesartan; LPO, lipoprotein oxide; DCF, 2,7-dichlorofluorescein; DCFH-DA, 2,7-dichlorodihy-
drofluorescein-diacete.
a P 
 0.05, b P 
 0.005, c P 
 0.001 vs. control
d P 
 0.05 vs. DM
e P 
 0.05 vs. DM  QUI
Blood glucose was measured by Glutest E II (Kyoto Immunohistochemistry
Dai-iti Kagaku, Kyoto, Japan). Kidney slices were processed for immunohistochem-
istry using the labeled streptavidin biotin method as de-
Western blotting
scribed previously [35, 36]. Wax sections (2 m) were
As described in detail previously [35, 36], the right dewaxed, incubated first with 3% H2O2 for 10 minutes to
kidneys were removed immediately after perfusion with eliminate endogenous peroxidase activity and thereafter
PBS. They were homogenized on ice with a Teflon-glass with a monoclonal antibody directed against p47phox,
tissue homogenizer (Iwaki, Chiba, Japan), in 4 mL of buf- eNOS and nNOS (Transduction Laboratories) at 1:100
fer containing 20 mmol/L Tris, at pH 7.2, 0.5 mmol/L dilution for four hours after exposure to blocking serum.
ethylenediaminetetraacetic acid (EDTA), 0.5 mmol/L The sections were rinsed with TBST and biotinylated sec-
ethylene glycol-bis (-aminoethyl ether)-N,N,N,N-tetra- ondary antibody against mouse IgG (Dako) for one hour.
acetic acid (EGTA), 20 mol/L leupeptin, 10 mmol/L After rinsing with TBST, the sections were incubated
dithiothreitol, 0.1 mmol/L phenylmethylsulfonyl fluoride for one hour with HRP-conjugated streptavidin solution
and 0.1 mmol/L Pefabloc SC. Homogenates were centri- (Dako). HRP labeling was detected using a peroxide
fuged at 4C and 12,000 rpm for 15 minutes. The superna- substrate solution with 0.8 mmol/L DAB and 0.01%
tants were diluted in the same volume of sodium dodecyl H2O2. The sections were counterstained with hematoxy-
sulfate (SDS) sample buffer (0.125 mol/L Tris-HCl, 10% lin before being examined under a light microscope.
2-mercaptoethanol, 4% SDS, 10% sucrose, 0.004% bro-
Statistical analysismophenol blue in final concentration). The amount of
protein was measured by the Bradford method (Bio- Data are presented as mean 	 SEM value. The differ-
Rad, Richmond, CA, USA). Samples containing 25 g ence among the four groups was evaluated by one-way
of protein were applied to 4 to 20% gradient gel (Daiichi ANOVA followed by the Bonferroni method where ap-
Pure Chemicals Co., Tokyo, Japan) and electroblotted propriate. Comparisons of urinary and plasma LPO be-
to nitrocellulose membranes. The membranes were incu- tween groups were made by Mann-Whitney nonpara-
bated with 5% nonfat dried milk in Tris buffered saline metric test since the values were not normally distributed.
containing 0.1% Tween 20 (TBST) for 30 minutes, fol-
lowing overnight incubation with monoclonal antibody
RESULTS
for p47phox, endothelial nitric oxide synthase (eNOS),
Physiological dataneuronal nitric oxide synthase (nNOS; Transduction La-
boratories, Lexington, KY, USA) and nitrotyrosine (Up- Blood glucose concentration of rats with DM was con-
siderably higher than that of the controls but was notstate Technology, Lake Placid, NY, USA) in a 1:1000
dilution. After rinsing in TBST, membranes were in- affected by ACEI or ARB (Table 1). The body weights
were significantly lower in rats with DM than in controlscubated for two hours with a horseradish peroxidase
(HRP)-conjugated secondary antibody against mouse during the experimental period. This effect was en-
hanced significantly in rats given the ACEI. The meanIgG (Dako, Glostrup, Denmark) at a 1:1000 dilution,
and rinsed with TBST followed by 0.8 mmol/L diamino- blood pressure (measured under anesthesia) and the cre-
atinine clearance (measured from 24-hour urine collec-benzidine (DAB; Dojindo Laboratories, Kumamoto, Ja-
pan) with 0.01% H2O2 and 3 mmol/L NiCl2 for the detec- tions) were similar in the four groups. Diabetic animals
have a substantial increase in renal albumin excretion,tion of blots.
Onozato et al: Diabetic nephropathy 189
Fig. 1. Light micrographs illustrating immu-
nostaining for NAD(P)H oxidase p47phox in
glomerulus (a, c, e, g) and inner medulla (b,
d, f, h). (a, b) control rat; (c, d) diabetic rat;
(e, f) diabetic treated with quinapril; (g, h)
diabetic treated with candesartan. Magnifica-
tion 280.
which was reduced to values not significantly different to normalize the immunostaining. The quantitative anal-
ysis of p47phox protein in the kidney by Western blotfrom control animals by the ACEI and the ARB.
showed a specific band corresponding to a molecular
Expression of p47phox weight of 47 kD. Densitometry of this band confirmed
an increase in protein amount in rats with DM comparedThe p47phox cytosolic component of NAD(P)H oxi-
dase was expressed in control rats in the glomeruli, the to control (0.32 	 0.02 vs. 0.21 	 0.01 arbitrary units;
P 
 0.0005). This was suppressed significantly by bothdistal tubules in the cortex and thin limbs of the loops
of Henle, and the medullary collecting ducts in medulla. ACEI (0.24	 0.02, P
 0.005 vs. DM) and ARB (0.23	
0.01; P
 0.002 vs. DM) to values not significantly differ-Its expression at these sites appeared enhanced in rats
with DM (Fig. 1). Both the ACEI and the ARB appeared ent from control rats (Fig. 2).
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control in diabetic rats treated with ACEI (0.25 	 0.01)
or ARB (0.21 	 0.02 arbitrary units).
The production of oxidative products of NO in the
kidneys was evaluated by measurement of nitrosylated
proteins by Western blot. As in previous studies [39],
several bands were detected in the kidney, as would be
anticipated from the pleomorphic nature of proteins with
nitrosylated tyrosine residues. The strongest band had
a molecular weight about 60 kD. Densitometry of this
band showed a modest increase in nitrosylated protein
density in rats with DM (0.29 	 0.02 vs. 0.24 	 0.05
arbitrary units, P 
 0.05). This was reduced to values
not different from controls by the ACEI (0.24 	 0.01)
and the ARB (0.23 	 0.02, Fig. 6).
Renal albumin excretion
Renal albumin excretion was used as a marker for
Fig. 2. Western blot for p47phox using whole kidney homogenate ana- early diabetic nephropathy. Albumin excretion was ele-lyzed by densitometry (mean 	 SEM from 6 rats in each group). A
vated significantly in rats with DM at four weeks afterprominent band for p47phox is observed at 47 kD. Abbreviations are:
DM, streptozotocin-induced diabetic rats; DM  QUI, diabetic rats induction of diabetes (Table 1). Both the ACEI and the
given quinapril; DM  CAN, diabetic rats given candesartan. *P 
 ARB reduced renal albumin excretion significantly in
0.0005 vs. Control; P 
 0.005, P 
 0.002 vs. DM.
DM. Although the final values for proteinuria were not
different in these two groups, quinapril appeared some-
what more effective than candesartan (Fig. 7).
Plasma LPO and hydrogen peroxide production
in the kidney DISCUSSION
Plasma lipid peroxidation products (LPO) were in- The main new findings of this study are that rats with
creased in rats with DM. This was reduced significantly early proteinuric diabetes mellitus have evidence of oxi-
in rats with DM treated with ACEI and ARB to levels dative stress associated with enhanced renal expression
of control rats (Table 1). The H2O2 production in the of p47phox and eNOS and nitrotyrosine. All of these
kidney measured by DCF generation was significantly changes are prevented in rats given an ACEI or an ARB
increased in DM. Both ACEI and ARB treatments re- for two weeks before the study.
duced the hydrogen peroxide production significantly to
the control level (Table 1). NAD(P)H oxidase expression and its
oxidative products
Expression of NOS isoforms and nitrosylation
The pathophysiology of diabetic nephropathy has beenof proteins
related to oxidative stress leading to an enhanced expres-
Immunohistochemical studies showed expression of sion of TGF-1and fibronectin [4, 40, 41]. However, the
type I or nNOS in the macula densa, whose expression source of ROS in the kidney remains undefined. Studies
seemed to be slightly increased in DM but did not change in models of hypertension or atherosclerosis have linked
by each treatment (Fig. 3). Western blot analysis of oxidative stress in the blood vessel to O2 generated by
whole kidney homogenates showed a band of 160 kD NAD(P)H oxidase in endothelial and vascular smooth
corresponding to nNOS whose densitometry showed no muscle cells [42]. Hyperglycemia can increase the expres-
differences between the four groups (control 0.27	 0.02, sion of p47phox in leukocytes [43]. In this study, p47phox
DM 0.28 	 0.03, DM  QUI 0.23 	 0.03, DM  CAN expression indeed was enhanced in the kidneys of hyper-
0.22 	 0.04 arbitrary units; NS; Fig. 4). glycemic, diabetic rats with prominent expression in re-
The immunohistochemical study showed a prominent nal vasculature, the thin limb of the loop of Henle, mac-
expression of type III or eNOS in the endothelium of ula densa cells, distal convoluted tubules and collecting
glomeruli, renal arteries and arterioles that appeared ducts. Although not studied quantitatively by Western
more prominent in those with DM, but was reduced in analysis, these immunohistochemical findings suggest
those given an ACEI or an ARB (Fig. 3). Western blot that there may be enhanced expression of p47phox in
analysis (Fig. 5) confirmed a modest increase in eNOS the cortex and the medulla. However, our data dissociate
expression in rats with DM (0.29 	 0.01 vs. 0.24 	 0.01 the activation of p47phox and eNOS, and the develop-
ment of oxidative stress in DM from hyperglycemia itself,arbitrary units, P 
 0.05), which was not different from
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Fig. 3. Light micrographs illustrating immu-
nostaining for neuronal nitric oxide synthase
(nNOS) and endothelial nitric oxide synthase
(eNOS). Immunoreactivity for nNOS is ob-
served in macula densa and that for eNOS is
in endothelial cells in glomerulus and renal
artery. Magnification 280 for nNOS, 240
for eNOS in glomerulus and 180 for eNOS
in renal artery.
since the administration of an ACEI or an ARB failed spontaneously hypertensive rat (SHR), yet only the
ARB corrected oxidative stress and restored nitric oxideto modify the hyperglycemia yet fully prevented the in-
creased expression of p47phox, eNOS and their products signaling in the juxtaglomerular apparatus [23].
including nitrotyrosine, plasma LPO and renal H2O2 in
NOS and nitrotyrosine expression in the kidneydiabetic rats. Recently, enhanced gp91phox NADPH ox-
idase and eNOS expression in aorta have been demon- Our findings address the controversy concerning the
contribution of different NOS isoforms to intrarenal pro-strated in the early stage of streptozotocin-induced dia-
betic rats [44], supporting our findings of oxidative stress duction of NO in diabetes. On the one hand, a stimulated
renal NO system has been postulated to underlie thein the kidney of diabetic rats.
Angiotensin II stimulated NAD(P)H oxidase activity persistent hyperfiltration that precedes proliferative and
sclerotic events in the glomeruli culminating in protein-and expression of p22phox and p67phox in VSMCs [25,
26, 42]. Both the ACEI and the ARB suppressed uric azotemia [21, 46–48]. We detected an increased ex-
pression of eNOS in microvessels and kidneys of ratsp47phox expression significantly in the kidney of diabetic
rats. These results are consistent with a previous report with DM. This confirms reports in rats with established
DM [1, 21, 49]. In contrast, a study in rats with earlyof a reduction in the mRNA for NAD(P)H oxidase in
vascular smooth muscle cells of rats with DM by an ARB DM detected no changes in renal eNOS protein expres-
sion [50]. This may relate to the time course of induction[45] that was independent of blood sugar. We have found
that two weeks of treatment with an ARB or non-specific of diabetes [21]. eNOS is expressed significantly also in
tubular epithelial cells, which may therefore have con-antihypertensive therapy with hydralazine, hydrochloro-
thiazide and reserpine normalized blood pressure in the tributed to the increased eNOS protein expression de-
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Fig. 4. Western blot studies of nNOS expression in the whole kidney
Fig. 6. Western blot of nitrotyrosine in whole kidney homogenateshomogenates showing a specific band at 160 kD. The bands were quanti-
quantified by densitometry (mean 	 SEM from 6 rats in each group).fied by densitometry and expressed as mean 	 SEM values from six
There was a proximate band at 60 kD. *P 
 0.05 vs. Control; P 
rats in each group.
0.05, P 
 0.01 vs. DM.
Fig. 5. Western blot of eNOS expression in the whole kidney homoge- Fig. 7. Albumin excretion in control rats and over four weeks of diabe-
nates were quantified by densitometry (mean 	 SEM from 6 rats in tes mellitus alone or with two weeks of quinapril or candesartan adminis-
each group). A specific band for eNOS was observed at 133 kD. *P 
 tration (weeks 2–4). Symbols are: () Control; () DM; () DM 
0.05 vs. Control; P 
 0.001 vs. DM. QUI; () DM  CAN; *P 
 0.005 vs. Control; P 
 0.05, P 

0.02 vs. DM.
tected by Western analysis in whole kidneys of diabetic
to the accompanying glomerular hyperfiltration. In ourrats. However, immunohistochemical studies do not de-
model of insulinogenic diabetes without insulin replace-tect prominent expression of eNOS protein in tubules
ment, no increase in nNOS protein expression in the[35]. Therefore, tubular expression of eNOS could not
kidney was detected, nor was evidence of glomerularbe assessed in this study. We could not confirm an in-
hyperfiltration as assessed indirectly from 24-hour creati-crease in nNOS expression in the kidney of diabetic
nine clearance. It is possible that the difference betweenrats that others reported using immunohistochemistry
our study and those of others may relate to the severity of[47, 48], Western analysis [1, 50] or reverse transcription-
diabetes and the degree of accompanying hyperglycemia.polymerase chain reaction (RT-PCR) analysis [50]. The
prior increases in nNOS expression have been related Indeed, glucose concentrations above 350 to 500 mg/dL
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bond covalently with NO, thereby curtailing NO bioac- of AT1-receptor induced expression of a range of patho-
tivity [51]. logic process in the kidney. Prominent among these may
Studies in the peripheral circulation of patients with be p47phox-induced activation of NAD(P)H oxidase-
diabetes, and the renal vessels of animal models, have dependent O2 generation and eNOS-induced NO gen-
concluded that there is a defective EDRF response to eration leading to the formation of oxidative and nitro-
endothelial agonists such as acetylcholine [52]. This sative products including ONOO. Intense interest is
could be explained if NO is scavenged in the diabetic focused on the cellular events linking AT1 receptor acti-
kidney by over-production of O2 . Any ensuing increase vation to expression of cytokines and growth factors such
in ONOO production should enhance nitrotyrosine de- as TGF- in the kidneys of diabetics that predispose
position. An example is the kidney of the SHR in which them to the development of nephropathy. The present
an increase in oxidative stress is accompanied by in- findings suggest that co-expression of NAD(P)H oxidase
creased nitrotyrosine deposition [39]. Indeed, an increase and eNOS, leading to increased nitro-oxidative stress,
in nitrotyrosine deposition has been detected in the pla- could be one such factor. Intervention studies to block
centa of diabetic patients where it has been related to NAD(P)H oxidase or eNOS are needed to address this
vascular damage [15]. Moreover, immunocytochemical hypothesis directly.
studies in human renal biopsies reveal an increase in
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